Low LDL-C levels are associated with risk of mortality in a Chinese cohort study

被引:0
作者
Jie-Ming Lu
Meng-Yin Wu
Zong-Ming Yang
Yao Zhu
Die Li
Zhe-Bin Yu
Peng Shen
Meng-Ling Tang
Ming-Juan Jin
Hong-Bo Lin
Li-Ming Shui
Kun Chen
Jian-Bing Wang
机构
[1] Zhejiang University School of Public Health,Department of Epidemiology and Biostatistics
[2] Zhejiang,Department of Chronic Disease and Health Promotion
[3] Yinzhou District Center for Disease Control and Prevention,Department of Epidemiology and Biostatistics, Cancer Institute, the Second Affiliated Hospital
[4] Zhejiang University School of Medicine,Department of Epidemiology and Biostatistics, the Children’s Hospital, National Clinical Research Center for Child Health
[5] Yinzhou District Health Bureau of Ningbo,undefined
[6] Ningbo,undefined
[7] Zhejiang University School of Medicine,undefined
来源
Endocrine | 2021年 / 73卷
关键词
LDL-C0; Mortality; Cardiovascular disease; Stroke; Cancer;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:563 / 572
页数:9
相关论文
共 342 条
[1]  
Ference BA(2017)Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel Eur. Heart J. 38 2459-2472
[2]  
Ginsberg HN(2012)The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials Lancet 380 581590-2567
[3]  
Graham I(2019)The Association between low-density lipoprotein cholesterol and incident atherosclerotic cardiovascular disease in older adults: results from the national institutes of health pooled cohorts J. Am. Geriatr. Soc. 67 2560-1297
[4]  
Ray KK(2016)Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis Jama 316 1289-489
[5]  
Packard CJ(2016)A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality J. Clin. Lipidol. 10 472-953
[6]  
Bruckert E(2016)Chinese guidelines on prevention and treatment of dyslipidemia in adults(2016 revison) Chin. Circ. J. 31 937-60
[7]  
Hegele RA(2014)An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia—full report J. Clin. Lipidol. 8 29-488
[8]  
Krauss RM(2014)National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1—executive summary J. Clin. Lipidol. 8 473-188
[9]  
Raal FJ(2020)2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk Eur. Heart J. 41 111-S45
[10]  
Schunkert H(2014)2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults Circulation 129 S1-244